acquired
Stage
2003
Founded
3
Investors
About
Genkyotex was a clinical-stage biotechnology company focused on developing novel NOX inhibitors for the treatment of severe diseases, particularly fibrotic and inflammatory conditions. The company was acquired by Calliditas Therapeutics in 2020.
Explore Genkyotex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.